Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 5.01 AUD -0.6% Market Closed
Updated: Jun 3, 2024

Mayne Pharma Group Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mayne Pharma Group Ltd
Accounts Receivables Peer Comparison

Comparables:
NEU
BOT
PBP
C
CU6
VLS

Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Mayne Pharma Group Ltd
ASX:MYX
Accounts Receivables
AU$177.4m
CAGR 3-Years
-3%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Accounts Receivables
AU$18.6m
CAGR 3-Years
191%
CAGR 5-Years
82%
CAGR 10-Years
27%
Botanix Pharmaceuticals Ltd
ASX:BOT
Accounts Receivables
AU$219.6k
CAGR 3-Years
-68%
CAGR 5-Years
N/A
CAGR 10-Years
7%
Probiotec Ltd
ASX:PBP
Accounts Receivables
AU$34.7m
CAGR 3-Years
40%
CAGR 5-Years
14%
CAGR 10-Years
16%
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vita Life Sciences Ltd
ASX:VLS
Accounts Receivables
AU$11.2m
CAGR 3-Years
17%
CAGR 5-Years
10%
CAGR 10-Years
9%

See Also

What is Mayne Pharma Group Ltd's Accounts Receivables?
Accounts Receivables
177.4m AUD

Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Accounts Receivables amounts to 177.4m AUD.

What is Mayne Pharma Group Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
-7%

Over the last year, the Accounts Receivables growth was -32%. The average annual Accounts Receivables growth rates for Mayne Pharma Group Ltd have been -3% over the past three years , -7% over the past five years .